Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
复制标题
索拉非尼和舒尼替尼与 Enzastaurin(一种选择性蛋白激酶 C 抑制剂)在肾细胞癌细胞系中的协同作用。
DOI:
10.1016/j.canlet.2008.12.013
复制
发表时间:
2009
期刊:
影响因子:
9.7
通讯作者:
M. Schmidinger
中科院分区:
文献类型:
--
作者:
U. Vogl;W. Berger;M. Micksche;C. Pirker;W. Lamm;Oskar Pichelmeyer;C. Zielinski;M. Schmidinger
Enzastaurin (LY317615.HCl) is an oral selective PKC-beta inhibitor with antiproliferative efficacy in various tumor models. This study was designed to investigate whether combination therapy with Enzastaurin and other targeted agents including Sorafenib and Sunitinib enhanced anti-tumor efficacy in renal cell carcinoma cell lines. Enzastaurin alone presented not active in renal cell carcinoma cell lines. Both Sorafenib and Sunitinib with Enzastaurin at concentrations feasible in vivo showed a synergistic reduction of viable RCC cells by inhibiting cell growth through inhibition of phospho-S6-kinase and GSK3-beta. The combination of Enzastaurin with Sorafenib and Sunitinib seems highly encouraging and warrants further investigation in vivo.
登录
查看更多内容
影响因子:
45.3
作者:
Motzer, RJ;Mazumdar, M;Ferrara, J
通讯作者:
Ferrara, J
影响因子:
15.9
作者:
Xia, P;Aiello, LP;King, GL
通讯作者:
King, GL
影响因子:
45.3
作者:
Motzer, RJ;Bacik, J;Mazumdar, M
通讯作者:
Mazumdar, M
DOI:
--
发表时间:
1996
期刊:
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
影响因子:
--
作者:
Sauma,S;Yan,Z;Ohno,S;Friedman,E
通讯作者:
Friedman,E
影响因子:
45.3
作者:
Robertson, Michael J.;Kahl, Brad S.;Shipp, Margaret A.
通讯作者:
Shipp, Margaret A.